{"id":122601,"date":"2026-03-14T04:38:35","date_gmt":"2026-03-14T07:38:35","guid":{"rendered":"https:\/\/tech.einnews.com\/article\/899346014"},"modified":"2026-03-14T04:38:35","modified_gmt":"2026-03-14T07:38:35","slug":"kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos","status":"publish","type":"post","link":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/2026\/03\/14\/kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos\/","title":{"rendered":"Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs"},"content":{"rendered":"
<\/div>\n
To read the full story, subscribe<\/a> or sign in<\/a>.<\/div>\n
\n
\n

March 13, 2026<\/p>\n

By Marian (YoonJee) Chu<\/a><\/div>\n
No Comments<\/a><\/div>\n<\/div>\n<\/div>\n

Two biotech and three med-tech companies are slated for Kosdaq debuts this month, signaling a potential rebound for Korea financings in 2026. Kanaph Therapeutics Inc. will open with a \u20a940 billion (US$26.99 million) raise and Imbiologics Corp. will debut with \u20a952 billion. Additionally, Mezoo Co. Ltd., Cosmo Robotics Co. Ltd. and Recensmedical Inc. will launch IPOs.<\/p>\n

BioWorld<\/a> <\/span>Financings<\/a> <\/span>Medical technology<\/a> <\/span>Wearable<\/a> <\/span>Aging<\/a> <\/span>Cancer<\/a> <\/span>Dermatologic<\/a> <\/span>Immune<\/a> <\/span>Antibody<\/a> <\/span>Antibody-drug conjugate<\/a> <\/span>Bispecific antibody<\/a> <\/span>Small molecule<\/a> <\/span>IPO<\/a> <\/span>Asia-Pacific<\/a><\/span><\/p>\n

<\/a><\/strong> <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Two biotech and three med-tech<\/span> companies are slated for Kosdaq … launch IPOs. BioWorld Financings Medical technology<\/span> Wearable Aging Cancer Dermatologic Immune …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-122601","post","type-post","status-publish","format-standard","hentry","category-news","wpcat-1-id"],"_links":{"self":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/posts\/122601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/comments?post=122601"}],"version-history":[{"count":0,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/posts\/122601\/revisions"}],"wp:attachment":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/media?parent=122601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/categories?post=122601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/tags?post=122601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}